World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
38377
World Ranking
15873
National Ranking
1461

Overview

Jim Cassidy is affiliated with the University of Glasgow in the United Kingdom and has contributed extensively to the field of medicine, with a focus primarily in oncology. The bulk of their work revolves around colorectal cancer, particularly its treatments and studies.

The main fields of Cassidy's research include Medicine, with subfields in Oncology, Surgery, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, and Epidemiology. Their research topics emphasize colorectal cancer treatments and studies, cancer treatment and pharmacology, gastric cancer management and outcomes, genetic factors in colorectal cancer, colorectal cancer surgical treatments, colorectal cancer screening and detection, and shoulder and clavicle injuries.

Cassidy's recent publications demonstrate engagement with multiple aspects of cancer treatment and surgical interventions. Key papers include:

  • Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study (2023), published in Journal of Clinical Oncology
  • Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer (2023), published in Journal of Clinical Oncology
  • Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy (2024), published in JAMA Surgery
  • A bibliometric analysis of the 50 most cited articles on acromioclavicular joint reconstruction (2025), published in MUSCULOSKELETAL SURGERY

Frequent co-authors throughout Cassidy's career include Arié Figer, Leonard B. Saltz, Stephen Clarke, Eduardo Díaz-Rubio, and Werner Scheithauer. Collaboration with these researchers indicates a strong network in oncology and surgical research.

Publication venues where Cassidy's work appears most frequently are:

  • Journal of Clinical Oncology
  • JAMA Surgery
  • MUSCULOSKELETAL SURGERY

Overall, Cassidy's research centers on improving cancer therapies and understanding the complexities of colorectal cancer through clinical studies and surgical outcomes. Their multidisciplinary approach combines pharmacological treatment, surgery, and examination of genetic and epidemiological factors.

Best Publications

  • Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

    A. de Gramont;A. Figer;M. Seymour;M. Homerin

  • Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

    Leonard B. Saltz;Stephen Clarke;Eduardo Díaz-Rubio;Werner Scheithauer

  • Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

    Chris Twelves;Alfred Wong;Marek P. Nowacki;Markus Abt

  • Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

    Jean Yves Douillard;Salvatore Siena;James Cassidy;Josep Tabernero

  • Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study

    Eric Van Cutsem;Chris Twelves;Jim Cassidy;David Allman

  • Randomized Intergroup Trial of Cisplatin–Paclitaxel Versus Cisplatin–Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results

    Martine J. Piccart;Kamma Bertelsen;Keith James;Jim Cassidy

  • Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates

    Paul A. Vasey;Stan B. Kaye;Rosemary Morrison;Chris Twelves

  • Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

    Jim Cassidy;Stephen Clarke;Eduardo Díaz-Rubio;Werner Scheithauer

  • Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.

    Johannes Schüller;Jim Cassidy;Etienne Dumont;Brigitte Roos

  • XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer

    Jim Cassidy;Josep Tabernero;Chris Twelves;René Brunet

  • First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

    J. Cassidy;C. Twelves;E. Van Cutsem;P. Hoff

  • Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

    Jean Yves Douillard;S. Siena;J. Cassidy;J. Tabernero

  • Randomized Controlled Clinical Effectiveness Trial of Cognitive Behavior Therapy Compared With Treatment As Usual for Persistent Insomnia in Patients With Cancer

    Colin A. Espie;Leanne Fleming;James Cassidy;Leslie Samuel

  • Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties.

    N C Yip;I S Fombon;P Liu;S Brown

  • Capecitabine, an Oral Fluoropyrimidine Carbamate With Substantial Activity in Advanced Colorectal Cancer: Results of a Randomized Phase II Study

    Eric Van Cutsem;Michael Findlay;Bruno Osterwalder;Walter Kocha

  • Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

    W. Scheithauer;J. McKendrick;S. Begbie;M. Borner

  • Oxaliplatin-related side effects: characteristics and management.

    Jim Cassidy;Jean-Louis Misset

  • Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.

    Leonard W. Seymour;David R. Ferry;David J. Kerr;Daniel Rea

  • XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

    J Cassidy;S Clarke;E Díaz-Rubio;W Scheithauer

  • Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy

    A L Jones;A S Hill;M Soukop;A W Hutcheon

Frequent Co-Authors

Howard L. McLeod
Howard L. McLeod Utah Tech University
Stan B. Kaye
Stan B. Kaye Royal Marsden NHS Foundation Trust
Ruth Duncan
Ruth Duncan Cardiff University
David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust
Graeme I. Murray
Graeme I. Murray University of Aberdeen
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Andrew Briggs
Andrew Briggs University of Glasgow
David J. Kerr
David J. Kerr University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a variety of related healthcare careers and online degree options. Many students look to specialized fields that offer strong job growth and the flexibility of distance learning. For instance, for nurses aiming for advanced clinical roles, pursuing one of the cheapest DNP programs can make a Doctor of Nursing Practice both accessible and affordable.

Pharmacy is another in-demand field. Modern online pharmacy schools make it easier for working professionals or those with family commitments to pursue a Doctor of Pharmacy without sacrificing flexibility.

Behind the scenes, health information management professionals play a key role in healthcare data and administration. A health information management bachelor degree online is an ideal option for those interested in data, records, and system management in medical settings.

If you are looking for a fast entry into healthcare, obtaining a billing and coding credential is a popular path. Learn about medical billing and coding certification cost and discover programs that are recognized and budget-friendly.

Best Scientists Citing Jim Cassidy

Trending Scientists